行情

KIN

KIN

Kindred Bio
NASDAQ

实时行情|Nasdaq Last Sale

7.53
+0.16
+2.17%
交易中 14:33 11/19 EST
开盘
7.37
昨收
7.37
最高
7.68
最低
7.37
成交量
3.95万
成交额
--
52周最高
13.96
52周最低
5.96
市值
2.94亿
市盈率(TTM)
-4.5825
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

KIN 新闻

  • 分析师:iPhone 11需求强劲 获得“巨大”成功
  • 新浪财经.30分钟前
  • 无论谁赢得下月大选 英国将卷入新一波债务洪流
  • 新浪美股.33分钟前
  • 美国科技巨头反击美国议员反垄断担忧 回应来了
  • 新浪美股.43分钟前
  • 麻烦不断!电子烟巨头Juul因针对青少年推销再遭起诉
  • 新浪财经.2小时前

更多

所属板块

生物技术和医学研究
+2.21%
制药与医学研究
+0.76%

热门股票

名称
价格
涨跌幅

KIN 简况

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
展开

Webull提供Kindred Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。